Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026

Rhea-AI Summary

Resmed (NYSE: RMD) reported Q4 FY2026 revenue of $1.46 billion, up 9% (8% in constant currency), with GAAP diluted EPS of $2.64 and non-GAAP diluted EPS of $2.95, up 16%. Q4 non-GAAP gross margin rose 90 bps to 62.3%, while GAAP gross margin was 58.8% including $41.9 million in Astral field safety notification expenses.

For FY2026, revenue increased 10% to $5.65 billion, GAAP gross margin improved 170 bps to 61.1%, and GAAP operating margin reached 33.4%. Non-GAAP diluted EPS grew 17% to $11.17. Free cash flow was $1.65 billion, supporting $1.0 billion of capital returned to shareholders, over 70% higher than the prior year. Resmed guided to returning more than $1.85 billion in FY2027 and raised its quarterly dividend by 10% to $0.66 per share. The company agreed to sell its MatrixCare business, completed the Noctrix Health acquisition, and launched new AirSense 11 and AirCurve 11 devices in multiple markets.

Positive

• Q4 revenue up 9% to $1.46 billion; 8% constant currency
• FY2026 revenue up 10% to $5.65 billion; 8% constant currency
• FY2026 non-GAAP diluted EPS $11.17, up 17% year over year
• FY2026 non-GAAP operating margin 36.1%, up 180 basis points
• FY2026 free cash flow $1.65 billion; operating cash flow $1.81 billion
• Capital returns $1.0 billion in FY2026; guiding to >$1.85 billion in FY2027 and 10% dividend increase to $0.66

Negative

• Q4 GAAP gross margin declined 200 basis points to 58.8%
• Q4 GAAP operating margin declined 300 basis points to 30.7%
• Q4 operating cash flow down 16% to $455 million; free cash flow down 21% to $404 million
• Astral field safety notification expenses totaled $41.9 million in FY2026
• FY2026 restructuring expenses of $21.7 million increased operating costs

News Explained

MatrixCare remains pre-close, while the higher quarterly dividend has an August 20 record date and September 24 payment date.

The MatrixCare sale remains an announced agreement, with closing expected during the first quarter of fiscal 2027; the disclosed transfer has not reached a reported closing.

At June 30, 2026, Resmed’s balance sheet classified assets and liabilities as held for sale.

For common holders, the board declared a $0.66 quarterly cash dividend, with an August 19, 2026 ex-dividend date, August 20, 2026 record date, and September 24, 2026 payment date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Q4 revenue increased by 9% to a record $1.5 billion; up 8% on a constant currency basis 
• Q4 GAAP diluted earnings per share up 2% to $2.64; non-GAAP diluted earnings per share up 16% to $2.95
• Returned $1.0 billion to shareholders through share repurchases and dividends during FY2026, an increase of more than 70%

Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended June 30, 2026.

“We closed fiscal year 2026 with strong fourth quarter results, reflecting continued momentum of our global business, sustained demand for our market-leading products, and disciplined execution of our strategy,” said Resmed’s Chairman and CEO, Mick Farrell.

“Year-over-year, we delivered 9% reported revenue growth, 90 basis points of gross margin expansion, and a 16% increase in earnings per share. For full year 2026, our $1.6 billion in free cash flow enabled us to invest in innovation, strengthen our market leadership, and return more than $1 billion to our shareholders.”

“As we enter fiscal year 2027, we will leverage our global scale and enhance our digital capabilities to benefit our patients, providers, and customers. We will use our industry-leading portfolio to improve patient outcomes, reduce healthcare costs, and drive long-term profitable growth for our shareholders.”

Financial Highlights

• FY 2026 revenue increased by 10% to $5.7 billion; up 8% on a constant currency basis
• FY 2026 GAAP gross margin up 170 bps to 61.1%; non-GAAP gross margin up 240 bps to 62.4%
• FY 2026 GAAP operating margin up 70 bps to 33.4%, non-GAAP operating margin up 180 bps to 36.1%
• FY 2026 GAAP diluted earnings per share of $10.43; non-GAAP diluted earnings per share of $11.17, an increase of 17%
• FY 2026 operating cash flow of $1.8 billion; free cash flow of $1.6 billion
• Guiding to more than $1.85 billion in capital to be returned to shareholders through share repurchases and dividends during FY 2027; announced quarterly dividend increase of 10% to $0.66 per quarter

Other Business and Operational Highlights

• Announced agreement to sell MatrixCare business; transaction expected to close during the first quarter of Resmed’s fiscal year 2027.
• Completed acquisition of Noctrix Health, a medical device company selling FDA De Novo classified wearable therapeutics for Restless Leg Syndrome, or RLS.
• Partnered with ŌURA to expand access to sleep health education and pathways to care, helping more people sleep better and improve their overall health.
• Following other successful launches in APAC, EMEA and the Americas, launched AirSense 11 in Taiwan. Additionally, launched AirCurve 11 ST/ST-A in the U.S. and AirTouch F30i Comfort in Brazil and Chile.
  

Financial Results and Operating Metrics
Unaudited; $ in millions, except for per share amounts

	Three Months Ended
	June 30, 2026				June 30, 2025				% Change			Constant Currency(A)
Revenue	$	1,464			$	1,348			9	%		8	%
Gross margin		58.8	%			60.8	%		(200) bps
Non-GAAP gross margin(B)		62.3	%			61.4	%		90 bps
Research and development expenses		106				86			22			19
Selling, general, and administrative expenses		296				267			11			8
Non-GAAP selling, general, and administrative expenses(B)		291				265			10			7
Income from operations		449				455			(1	)
Operating margin		30.7	%			33.7	%		(300) bps
Non-GAAP income from operations(B)		515				476			8
Non-GAAP operating margin		35.2	%			35.3	%		(10) bps
Net income		383				380			1
Non-GAAP net income(B)		428				375			14
Diluted earnings per share	$	2.64			$	2.58			2
Non-GAAP diluted earnings per share(B)	$	2.95			$	2.55			16
Operating cash flow		455				539			(16	)
Free cash flow(C)		404				508			(21	)

	Twelve Months Ended
	June 30, 2026				June 30, 2025				% Change			Constant Currency(A)
Revenue	$	5,653			$	5,146			10	%		8	%
Gross margin		61.1	%			59.4	%		170 bps
Non-GAAP gross margin(B)		62.4	%			60.0	%		240 bps
Research and development expenses		378				331			14			12
Selling, general, and administrative expenses		1,120				993			13			10
Non-GAAP selling, general, and administrative expenses(B)		1,108				991			12			9
Income from operations		1,887				1,685			12
Operating margin		33.4	%			32.7	%		70 bps
Non-GAAP income from operations(B)		2,039				1,763			16
Non-GAAP operating margin		36.1	%			34.3	%		180 bps
Net income		1,523				1,401			9
Non-GAAP net income(B)		1,632				1,407			16
Diluted earnings per share	$	10.43			$	9.51			10
Non-GAAP diluted earnings per share(B)	$	11.17			$	9.55			17
Operating cash flow		1,806				1,752			3
Free cash flow(C)		1,650				1,662			(1	)

(A) In order to provide a framework for assessing how our underlying businesses performed, excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency” basis, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

(B) See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

(C) Free cash flow is equal to operating cash flow less purchases of property, plant and equipment. 

Discussion of Fourth Quarter Results
All comparisons are to the prior year period unless otherwise noted

• Strong revenue growth: Revenue increased 9% (8% in constant currency) to approximately $1.5 billion, driven by strong demand across sleep devices, masks, accessories, and software solutions.
  
  
• Global momentum: Americas Sleep and Breathing Health revenue grew 8%, Rest of World Sleep and Breathing Health grew 10% in constant currency, and Residential Care Software revenue increased 2% in constant currency.
  
  
• Healthy profitability: GAAP gross margin of 58.8%. Non-GAAP gross margin increased 90 basis points to 62.3%, predominantly from productivity pipeline execution. The primary difference is our $42 million Astral field safety notification expenses.
  
  
• Robust earnings growth: GAAP income from operations of $449 million and GAAP diluted earnings per share of $2.64. Non-GAAP income from operations increased 8% and non-GAAP diluted earnings per share grew 16% to $2.95, predominantly attributable to strong sales growth and gross margin improvement.
  
  
• Strong cash generation: Operating cash flow totaled $455 million and free cash flow totaled $404 million, supporting $287 million returned to shareholders through dividends and share repurchases while maintaining investment in innovation and growth initiatives.
  

Dividend program
The Resmed board of directors today declared a quarterly cash dividend of $0.66 per share, representing an increase of 10% over our previous quarterly dividend. The dividend will have a record date of August 20, 2026, payable on September 24, 2026. The dividend will be paid in U.S. currency to holders of Resmed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be August 19, 2026, for common stockholders and for CDI holders. Resmed has received a waiver from the ASX’s settlement operating rules, which will allow Resmed to defer processing conversions between its common stock and CDI registers from August 19, 2026, through August 20, 2026, inclusive. 

Webcast details
Resmed will discuss its fourth quarter fiscal year 2026 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on Resmed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q4 2026 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately three hours after the webcast by dialing +1 877-660-6853 (U.S.) or +1 201-612-7415 (outside U.S.) and entering the passcode 13761408. The telephone replay will be available until August 20, 2026.

About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.

Safe harbor statement
Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding Resmed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, our supply chain, domestic and international regulatory developments, litigation, tax outlook, and the expected impact of macroeconomic conditions of our business – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in Resmed’s periodic reports on file with the U.S. Securities & Exchange Commission. Resmed does not undertake to update its forward-looking statements.

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations
(Unaudited; $ in thousands, except for per share amounts)

	Three Months Ended							Twelve Months Ended
	June 30, 2026			June 30, 2025				June 30, 2026				June 30, 2025
Net revenue	$	1,463,647		$	1,347,993			$	5,653,443			$	5,146,327
Cost of sales		552,245			520,068				2,128,040				2,060,753
Amortization of acquired intangibles(1)		8,301			9,367				31,779				32,116
Masks with magnets field safety notification expenses(1)		—			(1,512	)			—				(1,512	)
Astral field safety notification expenses(1)		41,885			—				41,885				—
Total cost of sales	$	602,431		$	527,923			$	2,201,704			$	2,091,357
Gross profit	$	861,216		$	820,070			$	3,451,739			$	3,054,970
Research and development		105,726			86,443				378,285				331,284
Selling, general, and administrative		290,655			265,125				1,108,042				991,019
Acquisition and portfolio review related expenses(1)		5,628			2,031				11,486				2,031
Total selling, general, and administrative		296,283			267,156				1,119,528				993,050
Amortization of acquired intangibles(1)		10,499			11,928				45,466				45,273
Restructuring expenses(1)		—			—				21,745				—
Total operating expenses	$	412,508		$	365,527			$	1,565,024			$	1,369,607
Income from operations	$	448,708		$	454,543			$	1,886,715			$	1,685,363
Other income (expenses), net:
Interest (expense) income, net	$	20,885		$	5,757			$	49,914			$	4,114
Gain (loss) attributable to equity method investments		2,232			1,269				6,955				3,644
Gain (loss) on equity investments		1,001			(2,533	)			(15,014	)			(10,299	)
Other, net		1,338			(983	)			(9,154	)			(5,256	)
Total other income (expenses), net		25,456			3,510				32,701				(7,797	)
Income before income taxes	$	474,164		$	458,053			$	1,919,416			$	1,677,566
Income taxes		90,732			78,348				396,123				276,843
Net income	$	383,432		$	379,705			$	1,523,293			$	1,400,723
Basic earnings per share	$	2.65		$	2.59			$	10.47			$	9.55
Diluted earnings per share	$	2.64		$	2.58			$	10.43			$	9.51
Non-GAAP diluted earnings per share(1)	$	2.95		$	2.55			$	11.17			$	9.55
Basic shares outstanding		144,706			146,472				145,523				146,716
Diluted shares outstanding		144,976			147,037				146,054				147,340

(1) See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets
(Unaudited; $ in thousands)

	June 30, 2026				June 30, 2025
Assets
Current assets:
Cash and cash equivalents	$	1,469,234			$	1,209,450
Accounts receivable, net		1,036,233				939,492
Inventories		945,805				927,711
Prepayments and other current assets		416,081				428,952
Assets held for sale	$	457,386			$	—
Total current assets	$	4,324,739			$	3,505,605
Non-current assets:
Property, plant, and equipment, net	$	581,829			$	550,790
Operating lease right-of-use assets		153,167				167,497
Goodwill and other intangibles, net		3,362,312				3,511,541
Deferred income taxes and other non-current assets		543,903				438,958
Total non-current assets	$	4,641,211			$	4,668,786
Total assets	$	8,965,950			$	8,174,391
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	308,923			$	278,157
Accrued expenses		494,921				402,253
Operating lease liabilities, current		29,141				30,506
Deferred revenue		162,911				166,030
Income taxes payable		98,108				132,274
Short-term debt		259,950				9,900
Liabilities held for sale	$	41,156			$	—
Total current liabilities	$	1,395,110			$	1,019,120
Non-current liabilities:
Deferred revenue	$	170,951			$	156,803
Deferred income taxes		64,640				77,682
Operating lease liabilities, non-current		137,413				153,015
Other long-term liabilities		213,028				141,520
Long-term debt		399,415				658,392
Total non-current liabilities	$	985,447			$	1,187,412
Total liabilities	$	2,380,557			$	2,206,532
Stockholders’ equity
Common stock	$	764			$	761
Additional paid-in capital		2,190,614				2,033,599
Retained earnings		7,255,121				6,081,490
Treasury stock		(2,778,591	)			(2,073,292	)
Accumulated other comprehensive income		(82,515	)			(74,699	)
Total stockholders’ equity	$	6,585,393			$	5,967,859
Total liabilities and stockholders’ equity	$	8,965,950			$	8,174,391

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows
(Unaudited; $ in thousands)

	Three Months Ended								Twelve Months Ended
	June 30, 2026				June 30, 2025				June 30, 2026				June 30, 2025
Cash flows from operating activities:
Net income	$	383,432			$	379,705			$	1,523,293			$	1,400,723
Adjustment to reconcile net income to cash provided by operating activities:
Depreciation and amortization		44,778				63,628				201,342				198,473
Amortization of right-of-use assets		10,343				10,660				42,810				37,338
Stock-based compensation costs		27,458				24,751				104,348				91,661
(Gain) loss attributable to equity method investments, net of dividends received		2,340				(1,269	)			(2,382	)			(3,644	)
(Gain) loss on equity investments		(1,000	)			2,533				15,014				10,299
Gain on previously held equity investment		(4,353	)			—				(4,353	)			—
Changes in operating assets and liabilities:
Accounts receivable, net		(37,209	)			(5,215	)			(96,778	)			(76,684	)
Inventories, net		(33,866	)			(32,133	)			(9,920	)			(80,165	)
Prepaid expenses, net deferred income taxes and other current assets		12,150				47,017				(140,260	)			82,629
Accounts payable, accrued expenses, income taxes payable and other		50,558				49,089				172,715				90,958
Net cash provided by (used in) operating activities	$	454,631			$	538,766			$	1,805,829			$	1,751,588
Cash flows from investing activities:
Purchases of property, plant, and equipment		(51,127	)			(30,585	)			(156,285	)			(89,865	)
Patent registration and acquisition costs		(5,384	)			(3,193	)			(18,670	)			(10,777	)
Purchases of intangible assets		(739	)			—				(2,218	)			—
Business acquisitions, net of cash acquired		(325,319	)			(138,578	)			(350,724	)			(139,248	)
Purchases of investments		(2,000	)			(2,013	)			(28,536	)			(6,416	)
Proceeds from exits of investments		—				250				2,752				4,628
Proceeds (payments) on maturity of foreign currency contracts		918				40,406				8,482				41,633
Net cash provided by (used in) investing activities	$	(383,651	)		$	(133,713	)		$	(545,199	)		$	(200,045	)
Cash flows from financing activities:
Proceeds from issuance of common stock, net		29,314				30,156				74,503				74,439
Purchases of treasury stock		(200,000	)			(100,008	)			(700,037	)			(300,025	)
Acquisition of consolidated subsidiary		—				(10,855	)			—				(10,855	)
Taxes paid related to net share settlement of equity awards		(388	)			(590	)			(21,833	)			(18,077	)
Payments of business combination contingent consideration		—				—				—				(855	)
Repayment of borrowings		(5,000	)			(5,000	)			(10,000	)			(40,000	)
Dividends paid		(87,090	)			(77,590	)			(349,662	)			(310,880	)
Net cash provided by (used in) financing activities	$	(263,164	)		$	(163,887	)		$	(1,007,029	)		$	(606,253	)
Effect of exchange rate changes on cash	$	905			$	35,573			$	6,183			$	25,799
Net increase (decrease) in cash and cash equivalents		(191,279	)			276,739				259,784				971,089
Cash and cash equivalents at beginning of period		1,660,513				932,711				1,209,450				238,361
Cash and cash equivalents at end of period	$	1,469,234			$	1,209,450			$	1,469,234			$	1,209,450

RESMED INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)

The measures “non-GAAP gross profit” and “non-GAAP gross margin” exclude amortization expense from acquired intangibles and field safety notification expenses and are reconciled below:

	Three Months Ended								Twelve Months Ended
	June 30, 2026				June 30, 2025				June 30, 2026				June 30, 2025
Revenue	$	1,463,647			$	1,347,993			$	5,653,443			$	5,146,327
GAAP cost of sales	$	602,431			$	527,923			$	2,201,704			$	2,091,357
Less:Amortization of acquired intangibles(A)		(8,301	)			(9,367	)			(31,779	)			(32,116	)
Less: Masks with magnets field safety notification expenses(A)		—				1,512				—				1,512
Less: Astral field safety notification expenses(A)		(41,885	)			—				(41,885	)			—
Non-GAAP cost of sales	$	552,245			$	520,068			$	2,128,040			$	2,060,753
GAAP gross profit	$	861,216			$	820,070			$	3,451,739			$	3,054,970
GAAP gross margin		58.8	%			60.8	%			61.1	%			59.4	%
Non-GAAP gross profit	$	911,402			$	827,925			$	3,525,403			$	3,085,574
Non-GAAP gross margin		62.3	%			61.4	%			62.4	%			60.0	%

The measures “non-GAAP selling, general, and administrative expenses” and “non-GAAP selling, general, and administrative expenses as a percentage of revenues” exclude acquisition and portfolio review related expenses and are reconciled below:

	Three Months Ended								Twelve Months Ended
	June 30, 2026				June 30, 2025				June 30, 2026				June 30, 2025
Revenue	$	1,463,647			$	1,347,993			$	5,653,443			$	5,146,327
GAAP selling, general, and administrative		296,283				267,156				1,119,528				993,050
Less:Acquisition and portfolio review related expenses(A)		(5,628	)			(2,031	)			(11,486	)			(2,031	)
Non-GAAP selling, general, and administrative		290,655				265,125				1,108,042				991,019
As a percentage of revenue:
GAAP selling, general, and administrative expenses		20.2	%			19.8	%			19.8	%			19.3	%
Non-GAAP selling, general, and administrative expenses		19.9	%			19.7	%			19.6	%			19.3	%

RESMED INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)
The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below:

	Three Months Ended							Twelve Months Ended
	June 30, 2026			June 30, 2025				June 30, 2026			June 30, 2025
GAAP income from operations	$	448,708		$	454,543			$	1,886,715		$	1,685,363
Amortization of acquired intangibles—cost of sales(A)		8,301			9,367				31,779			32,116
Amortization of acquired intangibles—operating expenses(A)		10,499			11,928				45,466			45,273
Restructuring(A)		—			—				21,745			—
Masks with magnets field safety notification expenses(A)		—			(1,512	)			—			(1,512	)
Astral field safety notification expenses(A)		41,885			—				41,885			—
Acquisition and portfolio review related expenses(A)		5,628			2,031				11,486			2,031
Non-GAAP income from operations	$	515,021		$	476,357			$	2,039,076		$	1,763,271

The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

	Three Months Ended								Twelve Months Ended
	June 30, 2026				June 30, 2025				June 30, 2026				June 30, 2025
GAAP net income	$	383,432			$	379,705			$	1,523,293			$	1,400,723
Amortization of acquired intangibles—cost of sales(A)		8,301				9,367				31,779				32,116
Amortization of acquired intangibles—operating expenses(A)		10,499				11,928				45,466				45,273
Restructuring expenses(A)		—				—				21,745				—
Gain on previously held equity investment(A)		(4,353	)			—				(4,353	)			—
Masks with magnets field safety notification expenses(A)		—				(1,512	)			—				(1,512	)
Astral field safety notification expenses(A)		41,885				—				41,885				—
Acquisition and portfolio review related expenses(A)		5,628				2,031				11,486				2,031
Tax benefit from business cessation(A)		—				(21,430	)			—				(21,430	)
Income tax effect of interest and penalties on income tax refunds(A)		—				—				—				(29,976	)
Income tax effect on non-GAAP adjustments(A)		(17,059	)			(5,544	)			(39,453	)			(20,448	)
Non-GAAP net income(A)	$	428,333			$	374,545			$	1,631,848			$	1,406,777
GAAP diluted shares outstanding		144,976				147,037				146,054				147,340
GAAP diluted earnings per share	$	2.64			$	2.58			$	10.43			$	9.51
Non-GAAP diluted earnings per share(A)	$	2.95			$	2.55			$	11.17			$	9.55

(A) Resmed adjusts for the impact of the amortization of acquired intangibles, restructuring expenses, gains on previously held equity investments, field safety notification expenses, acquisition and portfolio review related expenses and associated tax effects, in addition to tax benefits from business cessation, and the tax effect of interest and penalties on tax refunds from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.

Resmed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. Resmed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. Resmed believes this information provides investors better insight when evaluating Resmed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

RESMED INC. AND SUBSIDIARIES 

Revenue by Product and Region
(Unaudited; $ in millions, except for per share amounts)

	Three Months Ended
	June 30, 2026		(A)	June 30, 2025		(A)	% Change			Constant Currency(B)
Americas(C)
Devices	$	459		$	433		6	%
Masks and other		394			359		10
Total Americas(C)	$	853		$	792		8
Rest of World(C)
Devices	$	291		$	261		12	%		9	%
Masks and other		148			128		16			12
Total Rest of World(C)	$	439		$	389		13			10
Global revenue
Total Devices	$	750		$	694		8	%		7	%
Total Masks and other		542			487		11			10
Total Sleep and Breathing Health	$	1,292		$	1,181		9			8
Residential Care Software		172			167		3			2
Total	$	1,464		$	1,348		9			8

	Twelve Months Ended
	June 30, 2026		(A)	June 30, 2025		(A)	% Change			Constant Currency(B)
Americas(C)
Devices	$	1,768		$	1,654		7	%
Masks and other		1,513			1,343		13
Total Americas(C)	$	3,281		$	2,998		9
Rest of World(C)
Devices	$	1,124		$	1,011		11	%		6	%
Masks and other		572			497		15			9
Total Rest of World(C)	$	1,697		$	1,507		13			7
Global revenue
Total Devices	$	2,892		$	2,665		9	%		7	%
Total Masks and other		2,085			1,840		13			12
Total Sleep and Breathing Health	$	4,978		$	4,505		10			9
Residential Care Software		676			641		5			4
Total	$	5,653		$	5,146		10			8

(A)    Totals and subtotals may not add due to rounding.

(B)    In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

(C)    Historically we have presented our geographical split of revenue as “U.S., Canada, and Latin America” and “Combined Europe, Asia, and other markets”. Effective this quarter, this presentation has been renamed to Americas (formerly U.S., Canada, and Latin America) and Rest of World (formerly Combined Europe, Asia, and other markets). The methodology for attributing revenue to these geographies remains unchanged. Revenue from prior periods is consistent and comparable to previous reporting.

For investors	For media
+1 858-221-3304	+1 619-510-1281
investorrelations@resmed.com	news@resmed.com

FAQ

How did Resmed (RMD) perform in Q4 FY2026?

Resmed reported Q4 FY2026 revenue of $1.46 billion, up 9% year over year. According to Resmed, GAAP diluted EPS was $2.64 and non-GAAP diluted EPS was $2.95, up 16%, driven by strong device, mask, accessories, and software demand.

What were Resmed (RMD) full-year FY2026 financial results?

For FY2026, Resmed generated $5.65 billion in revenue, up 10% year over year. According to Resmed, GAAP diluted EPS reached $10.43 and non-GAAP diluted EPS $11.17, up 17%, with GAAP gross margin improving 170 basis points to 61.1%.

How much cash did Resmed (RMD) return to shareholders in FY2026 and what is the FY2027 guidance?

Resmed returned $1.0 billion to shareholders in FY2026 via dividends and buybacks, over 70% higher than the prior year. According to Resmed, it is guiding to returning more than $1.85 billion to shareholders during FY2027.

What is Resmed’s new dividend for Q4 2026 and key dates for RMD investors?

Resmed declared a quarterly dividend of $0.66 per share, a 10% increase. According to Resmed, the record date is August 20, 2026, ex-dividend date August 19, 2026, and payment date September 24, 2026.

What strategic transactions did Resmed (RMD) announce around Q4 FY2026?

Resmed agreed to sell its MatrixCare business, with closing expected in Q1 FY2027. According to Resmed, it also completed the acquisition of Noctrix Health, expanding into wearable therapeutics for Restless Leg Syndrome.

How did margins and cash flow trend for Resmed (RMD) in FY2026?

FY2026 GAAP gross margin rose to 61.1% and GAAP operating margin to 33.4%. According to Resmed, operating cash flow was $1.81 billion and free cash flow $1.65 billion, supporting increased shareholder returns and continued investment.

What new products and partnerships did Resmed (RMD) highlight in its Q4 FY2026 update?

Resmed launched AirSense 11 in Taiwan, AirCurve 11 ST/ST-A in the U.S., and AirTouch F30i Comfort in Brazil and Chile. According to Resmed, it also partnered with ŌURA to expand sleep health education and care pathways.